AstraZeneca Reports Promising Data From Lung Cancer Trial
09 August 2022 - 12:49PM
Dow Jones News
By Ian Walker
AstraZeneca PLC said Tuesday that initial results from a trial
of datopotamab deruxtecan-based combinations show promising
clinical activity in patients with advanced non-small-cell lung
cancer.
The pharmaceutical giant said that the trial showed encouraging
efficacy and safety results that justify further studies.
Datopotamab deruxtecan is being jointly developed by AstraZeneca
and Daiichi Sankyo.
"We look forward to continuing this important research with the
goal of providing a new, effective treatment option for patients
with advanced non-small-cell lung cancer," Astra's Chief Medical
Officer and Oncology Chief Development Officer Cristian Massacesi
said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 09, 2022 06:34 ET (10:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Daiichi Sankyo Company Ltd (PK) (OTCMarkets): 0 Nachrichtenartikel
Weitere Daiichi Sankyo Company Ltd (PK) News-Artikel